Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 5, 2025Open Access

Supplementary Figure 1 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited

View Full Paper
Ask AI
Bookmark
Share

Authors

LRLuis Gerardo Rodríguez‐LobatoOCOriol CardúsJMJoan Mañé-Pujol

Discussion

Loading...

Member takes

Overview

Observational analysis shows CAR T cell efficacy in myeloma, highlighting antigen expression complexity.

Key Points

  • CAR T cell therapy effectively controls myeloma even when BCMA expression is limited, indicating resilience.
  • Key evidence includes observation of antigen expression on different target cell lines demonstrating variability.
  • The approach involves an analysis of immune responses against distinct target cell lines expressing BCMA and CD229 antigens.
  • Implications of these findings suggest potential for broader application in cases with limited BCMA expression.

Cite This Study

Rodríguez‐Lobato et al. (2025) studied this question.

synapsesocial.com/papers/68c23a2cb210217d6477fb91https://doi.org/10.1158/2326-6066.30029647
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Supplementary Figure 6 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited2025
  2. 2Supplementary Figure 5 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited2025
  3. 3Supplementary Figure 2 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited2025
  4. 4Supplementary Figure 3 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited2025
  5. 5Supplementary Figure 4 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited2025